Latest Info on Dry Macular Generation as of 8/3/26
There’s still no cure, but a few updates…
The mainstays for slowing it are AREDS3 supplements — vitamins and antioxidants that reduce progression risk — plus lifestyle changes like quitting smoking and eating a healthy diet.
Dry macular degeneration treatments are broadening. OCU-410 was reported to slow growth of atrophic lesions by about 46%, and a drug called SYFOVRE has been approved for geographic atrophy. Stem cell therapy trials are ongoing, showing that transplanted cells can survive in the eye and may improve vision, but long-term safety and effectiveness still need confirmation. Let me know if you need more details.
There are a few more details. OCU-410 is being tested in a trial for geographic atrophy and has shown promising lesion reduction.
SYFOVRE is already approved and works by targeting complement pathways to slow disease progression.
There’s also EG-301, an investigational oral drug in development. For stem cell therapy, a first-of-its-kind trial using adult stem cell transplants is underway for advanced dry AMD, with early indications that patients experience some visual improvement, but long-term results are still being evaluated.
In the past few months, several treatments are being highlighted for dry AMD. Drugs like OPT-302, KSI-301, RGX-314, and AKST4290 are in the pipeline and expected to impact the market. OCU-410 continues to show promise in trials for geographic atrophy, and SYFOVRE remains an approved option that slows progression. Stem cell trials are also ongoing, but no new approvals have emerged yet.
One of the bigger stories is gene therapy. So, a company called Ocugen reported positive phase two results in March 2026 for a one-time treatment. It showed about a 31 percent reduction in lesion growth, but it’s Still early-stage, so, not approved yet.
For people who already have geographic atrophy, the two FDA-approved drugs still are Syfovre and Izervay. They can slow lesion growth, but don’t restore lost vision.
Over the past three to four months, photobiomodulation with the Valeda system got FDA clearance in November 2024. It’s a non-invasive light therapy that improves vision by about six letters and cuts the risk of new geographic atrophy by 73% over two years.
For the established injectables, Syfovre has five-year GALE extension data showing a cumulative delay in lesion growth of about 1.5 years. Izervay’s label was expanded for unlimited duration based on two-year data.
And on the pipeline side, Ocugen’s one-time gene therapy OCU410 received FDA RMAT designation after Phase two data showed a 31% reduction in lesion growth. Cognition Therapeutics also reported positive Phase two data for an oral pill called zervimesine, showing about 29% slower lesion growth at eighteen months.
Click Here to Learn How To Safely and Naturally Save Your Sight